Skip to main content

Advertisement

SpringerLink
Log in

Breast cancer cell CD200 expression regulates immune response to EMT6 tumor cells in mice

  • Preclinical study
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

CD200 has been characterized as an important immunoregulatory molecule, increased expression of which can lead to decreased transplant rejection, autoimmunity, and allergic disease. Elevated CD200 expression has been reported to be associated with poor prognosis in a number of human malignancies. We have found that cells of the transplantable EMT6 mouse breast cancer line growing in vitro express low levels of CD200, but levels increase markedly during growth in immunocompetent mice. Similar increased in vivo expression does not occur in NOD-SCID.IL-2γr−/− mice or mice with generalized over-expression of a CD200 transgene. In both mice, tumor growth occurs faster. Altered CD200 expression in control versus transgenic mice is accompanied by reproducible changes in tumor-infiltrating host cells, and altered cell composition in lymph nodes draining the tumor (DLN). Neutralization of expressed CD200 by anti-CD200mAbs leads to decreased tumor growth in immunocompetent mice, with improved detection of cytotoxic anti-tumor immune cells in DLN. Finally, we report that tumor growth in vivo can be monitored by levels of soluble CD200 (sCD200) in serum of tumor-bearing animals.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Kato M, Slack FJ (2008) Micro RNAS: small molecules with big roles—C. elegans to human cancer. Biol Cell 100:71–81

    Article  CAS  PubMed  Google Scholar 

  2. Dierks C, Grbic J, Zirlik K, Beigi R, Englund NP, Guo GR, Veelken H, Engelhardt M, Mertelsmann R, Kelleher JF, Schultz P, Warmuth M (2007) Essential role of stromally induced hedgehog signaling in B-cell malignancies. Nat Med 13:944–951

    Article  CAS  PubMed  Google Scholar 

  3. Salih HR, Kosowski SG, Haluska VF, Starling GC, Loo DT, Lee F, Aruffo AA, Trail PA, Kiener PA (2000) Constitutive expression of functional 4-1BB (CD137) ligand on carcinoma cells. J Immunol 165:2903–2910

    CAS  PubMed  Google Scholar 

  4. Ilvesaro JM, Merrell MA, Li L, Wakchoure S, Graves D, Brooks S, Rahko E, JukkolaVuorinen A, Vuopala KS, Harris KW, Selander KS (2008) Toll-like receptor 9 mediates CpG oligonucleotide-induced cellular invasion. Mol Cancer Res 6:1534–1543

    Article  CAS  PubMed  Google Scholar 

  5. Moreaux J, Hose D, Reme T, Jourdan E, Hundemer M, Legouffe E, Moine P, Bourin P, Moos M, Corre J, Möhler T, De Vos J, Rossi JF, Goldschmidt H, Klein B (2006) CD200 is a new prognostic factor in multiple myeloma. Blood 108:4194–4197

    Article  CAS  PubMed  Google Scholar 

  6. Petermann KB, Rozenberg GI, Zedek D, Groben P, McKinnon K, Buehler C, Kim WY, Shields JM, Penland S, Bear JE, Thomas NE, Serody JS, Sharpless NE (2007) CD200 is induced by ERK and is a potential therapeutic target in melanoma. J Clin Invest 117:3922–3929

    CAS  PubMed  Google Scholar 

  7. Moreaux J, Veyrune JL, Reme T, De Vos J, Klein B (2008) CD200: a putative therapeutic target in cancer. Biochem Biophys Res Commun 366:117–122

    Article  CAS  PubMed  Google Scholar 

  8. Siva A, Xin H, Qin F, Oltean D, Bowdish KS, Kretz-Rommel A (2008) Immune modulation by melanoma and ovarian tumor cells through expression of the immunosuppressive molecule CD200. Cancer Immunol Immunother 57:987–996

    Article  CAS  PubMed  Google Scholar 

  9. McWhirter JR, Kretz-Rommel A, Saven A, Maruyama T, Potter KN, Mockridge CI, Ravey EP, Qin FH, Bowdish KS (2006) Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation. Proc Nat Acad Sci USA 103:1041–1046

    Article  CAS  PubMed  Google Scholar 

  10. Tonks A (2007) CD200 as a prognostic factor in acute myeloid leukemia. Leukemia 21:566–568

    Article  CAS  PubMed  Google Scholar 

  11. Hoek RM, Ruuls SR, Murphy CA, Wright GJ, Goddard R, Zurawski SM, Blom B, Homola ME, Streit WJ, Brown MH, Barclay AN, Sedgwick JD (2000) Down-regulation of the macrophage lineage through interaction with OX2 (CD200). Science 290:1768–1771

    Article  CAS  PubMed  Google Scholar 

  12. Kretz-Rommel A, Qin FH, Dakappagari N, Ravey EP, McWhirter J, Oltean D, Frederickson S, Maruyama T, Wild MA, Nolan MJ, Wu DY, Springhorn J, Bowdish KS (2007) CD200 expression on tumor cells suppresses antitumor immunity: new approaches to cancer immunotherapy. J Immunol 178:5595–5605

    CAS  PubMed  Google Scholar 

  13. Kawasaki BT, Mistree T, Hurt EM, Kalathur M, Farrar WL (2007) Co-expression of the toleragenic glycoprotein, CD200, with markers for cancer stem cells. Biochem Biophys Res Commun 364:778–782

    Article  CAS  PubMed  Google Scholar 

  14. Rosenberg SA (2004) Cancer immunotherapy: moving beyond current vaccines. Nat Med 10:909–915

    Article  CAS  PubMed  Google Scholar 

  15. Gorczynski RM, Chen Z, He W, Khatri I, Sun Y, Yu K, Boudakov I (2009) Expression of a CD200 transgene is necessary for induction but not maintenance of tolerance to cardiac and skin allografts. J Immunol 183:1560–1568

    Article  CAS  PubMed  Google Scholar 

  16. Gorczynski RM, Cattral MS, Chen ZG, Hu JA, Lei J, Min WP, Yu G, Ni J (1999) An immunoadhesin incorporating the molecule OX-2 is a potent immunosuppressant that prolongs allo- and xenograft survival. J Immunol 163:1654–1660

    CAS  PubMed  Google Scholar 

  17. Jakobsen CG, Rasmussen N, Laenkholm A-V, Ditzel HJ (2007) Phage display-derived human monoclonal antibodies isolated by binding to the surface of live primary breast cancer cells recognize GRP78. Cancer Res 67:9507–9517

    Article  CAS  PubMed  Google Scholar 

  18. Andrews PD (2003) Aurora kinases: shining lights on the therapeutic horizon? Oncogene 24:5005–5015

    Article  Google Scholar 

  19. Wong K, Spaner DE, Gorczynski RM (2008) Lymphoma cell surface expression of CD200 modulates anti-tumor immunity (abstract). AAI, San Diego

    Google Scholar 

  20. Wu L, Tannock IF (2003) Repopulation in murine breast tumors during and after sequential treatments with cyclophosphamide and 5-fluorouracil. Cancer Res 63:2134–2138

    CAS  PubMed  Google Scholar 

  21. Diao J, Smythe JA, Smyth C, Rowe PB, Alexander IE (1999) Human PBMC-derived dendritic cells transduced with an adenovirus vector induce cytotoxic T-lymphocyte responses against a vector-encoded antigen in vitro. Gene Ther 6:845–853

    Article  CAS  PubMed  Google Scholar 

  22. Blobel CP (2005) ADAMS: key players in EGFR-signaling, development and disease. Nat Rev Mol Cell Biol 6:32–43

    Article  CAS  PubMed  Google Scholar 

  23. Gorczynski RM, Chen Z, Hu J, Kai Y, Lei J (2001) Evidence of a role for CD200 in regulation of immune rejection of leukaemic tumour cells in C57BL/6 mice. Clin Exp Immunol 126:220–229

    Article  CAS  PubMed  Google Scholar 

  24. Kretz-Rommel A, Qin F, Dakappagari N, Cofiell R, Faas SJ, Bowdish KS (2008) Blockade of CD200 in the presence or absence of antibody effector function: implications for anti-CD200 therapy. J Immunol 180:699–705

    CAS  PubMed  Google Scholar 

  25. Kawai O, Ishii G, Kubota K, Murata Y, Naito Y, Mizuno T, Aokage K, Saijo N, Nishiwaki Y, Gemma A, Kudo S, Ochiai A (2008) Predominant infiltration of macrophages and CD8(+) T cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer. Cancer 113:1387–1395

    Article  CAS  PubMed  Google Scholar 

  26. Gorczynski RM (2005) CD200 and its receptors as targets for immunoregulation. Curr Opin Invest Drugs 6:483–488

    CAS  Google Scholar 

  27. Sica A, Allavena P, Mantovani A (2008) Cancer related inflammation: the macrophage connection. Cancer Lett 267:204–215

    Article  CAS  PubMed  Google Scholar 

  28. Baumgartner J, Wilson C, Palmer B, Richter D, Banerjee A, McCarter M (2007) Melanoma induces immunosuppression by up-regulating FOXP3(+) regulatory T cells. J Surg Res 141:72–77

    Article  CAS  PubMed  Google Scholar 

  29. Hilchey SP, De A, Rimsza LM, Bankert RB, Bernstein SH (2007) Follicular lymphoma intratumoral CD4(+)CD25(+)GITR(+) regulatory T cells potently suppress CD3/CD28-costimulated autologous and allogeneic CD8(+)CD25(-) and CD4(+)CD25(-) T cells. J Immunol 178:4051–4061

    CAS  PubMed  Google Scholar 

  30. Sakaguchi S (2004) Naturally arising CD4(+) regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 22:531–562

    Article  CAS  PubMed  Google Scholar 

  31. Groux H (2003) Type 1 T-regulatory cells: their role in the control of immune responses. Transplantation 75:8S–12S

    Article  CAS  PubMed  Google Scholar 

  32. Jiang H, Chess L (2004) An integrated view of suppressor T cell subsets in immunoregulation. J Clin Invest 114:1198–1208

    CAS  PubMed  Google Scholar 

  33. Kapp JA, Kapp LM, McKenna KC (2004) Gamma delta T cells play an essential role in several forms of tolerance. Immunol Res 29:93–102

    Article  CAS  PubMed  Google Scholar 

  34. Young KJ, Zhang L (2002) The nature and mechanisms of DN regulatory T-cell mediated suppression. Hum Immunol 63:926–934

    Article  CAS  PubMed  Google Scholar 

  35. Gorczynski RM, Chen Z, Kai Y, Wong S, Lee L (2004) Induction of tolerance-inducing antigen-presenting cells in bone marrow cultures in vitro using monoclonal antibodies to CD200R. Transplantation 77:1138–1144

    Article  CAS  PubMed  Google Scholar 

  36. Gorczynski RM, Lee L, Boudakov I (2005) Augmented induction of CD4(+)CD25(+) Treg using monoclonal antibodies to CD200R. Transplantation 79:488–491

    Article  CAS  PubMed  Google Scholar 

  37. Nagaraj S, Gabrilovich DI (2008) Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Res 68:2561–2563

    Article  CAS  PubMed  Google Scholar 

  38. Cipriani B, Fridman A, Bendtsen C, Dharmapuri S, Mennuni C, Pak I, Mesiti G, Forni G, Monaci P, Bagchi A, Ciliberto G, LaMonica N, Scarselli E (2008) Therapeutic vaccination halts disease progression in BALB-neuT mice: the amplitude of elicited immune response is predictive of vaccine efficacy. Hum Gene Ther 19:670–680

    Article  CAS  PubMed  Google Scholar 

  39. Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ (2009) Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 58:49–59

    Article  CAS  PubMed  Google Scholar 

  40. Zhou JB, Zhang H, Gu PH, Bai JN, Margolick JB, Zhang Y (2008) NF-kappa B pathway inhibitors preferentially inhibit breast cancer stem-like cells. Breast Cancer Res Treat 111:419–427

    Article  CAS  PubMed  Google Scholar 

  41. Liu ET (2008) Functional genomics of cancer. Curr Opin Genet Develop 18:251–256

    Article  CAS  Google Scholar 

  42. Kuvaja P, Talvensaari-Mattila A, Turpeenniemi-Hujanen T (2008) High preoperative plasma TIMP-1 is prognostic for early relapse in primary breast carcinoma. Int J Cancer 123:846–851

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported by a POP II grant from the Canadian Institutes of Health Research (CIHR) to RMG.

Author information

Authors and Affiliations

  1. University Health Network, Toronto General Hospital, Room 2-805, MaRS Tower, 101 College Street, Toronto, M5G 1L7, Canada

    Reginald M. Gorczynski, Zhiqi Chen, Jun Diao, Ismat Khatri, Karrie Wong, Kai Yu & Julia Behnke

Authors
  1. Reginald M. Gorczynski
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zhiqi Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jun Diao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ismat Khatri
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Karrie Wong
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kai Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Julia Behnke
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Reginald M. Gorczynski.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gorczynski, R.M., Chen, Z., Diao, J. et al. Breast cancer cell CD200 expression regulates immune response to EMT6 tumor cells in mice. Breast Cancer Res Treat 123, 405–415 (2010). https://doi.org/10.1007/s10549-009-0667-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-009-0667-8

Keywords

Search

Navigation